The article provides an overview of recent developments in the healthcare sector, including Novo Nordisk's phase-out of ...

In the world of health, Novo Nordisk stops insulin pen production, Trump's potential health appointments draw attention, and ...

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...

The adjustment comes after a reassessment of the anticipated performance of Biogen's Alzheimer's treatment, Leqembi. The launch of Leqembi has not met the expectations set by analysts, leading to ...

The adjustment comes after a reassessment of the anticipated performance of Biogen's Alzheimer's treatment, Leqembi. The launch of Leqembi has not met the expectations set by analysts, leading to ...

Eisai Co (ESAIY) and Biogen Inc. (BIIB) announced that the latest findings for lecanemab-irmb, an anti-amyloid beta protofibril* antibody for the treatment of early Alzheimer’s disease, were ...

STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2024 ...

The company also raised its full-year profit guidance. Sales of its breakthrough Alzheimer's drug, Leqembi, along with new rare disease and depression treatments, helped offset a year-over-year ...

The only difference between the modified titration and the standard dosing regimen is the shift of one vial from the first infusion to the third infusion. Patients on the standard dosing regimen ...